Health and Healthcare

MannKind : MNKD

All MannKind Articles

305 Articles

Chris Lange | Nov 28, 2018 at 8:20 AM EST

Short Sellers Can’t Make Up Their Minds on Major Biotechs

The November 15 short interest data have been compared with the previous report, and short interest moves in the selected…

Chris Lange | Nov 12, 2018 at 8:50 AM EST

Short Sellers Raise the Stakes in Major Biotechs

The October 31 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Oct 25, 2018 at 8:20 AM EDT

Short Sellers Hike Their Bets in Major Biotechs

The October 15 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Oct 10, 2018 at 8:20 AM EDT

Short Sellers Back Off Major Biotechs

The September 28 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Sep 26, 2018 at 8:15 AM EDT

Major Biotechs Have Short Sellers on the Run

The September 14 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Sep 13, 2018 at 8:20 AM EDT

Short Sellers Up the Ante in Major Biotechs

24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The August 31 short interest data…

Chris Lange | Sep 5, 2018 at 10:05 AM EDT

Why MannKind Shares More Than Doubled This Week

MannKind shares are continuing their rally from Tuesday when it was announced that United Therapeutics was licensing MannKind a dry…

Chris Lange | Aug 27, 2018 at 7:05 AM EDT

Short Sellers Run for Cover From Major Biotechs

The August 15 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Aug 10, 2018 at 8:45 AM EDT

Why Have Short Sellers Backed Off Major Biotechs?

The July 31 short interest data have been compared with the previous report, and short interest in most of the…

Paul Ausick | Aug 6, 2018 at 4:04 PM EDT

Mannkind, Tesaro Can’t Escape Monday’s 52-Week Low Club

Mannkind, Tesaro, Acadia Pharmaceuticals, and Diebold Nixdorf all posted new 52-week lows Monday.

Paul Ausick | Aug 3, 2018 at 4:04 PM EDT

Symantec, Tesaro Plunge into Friday’s 52-Week Low Club

Symantec, Tesaro, Mannkind, and Western Digital all posted new 52-week lows Friday.

Chris Lange | Jul 25, 2018 at 7:10 AM EDT

Major Biotechs See a Rising Tide of Short Interest

The July 13 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Jul 12, 2018 at 8:21 AM EDT

Short Sellers Back Off Major Biotechs

The June 29 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Jun 27, 2018 at 9:00 AM EDT

Short Sellers Run for Cover From Major Biotechs

The June 15 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Jun 12, 2018 at 10:54 AM EDT

Short Sellers Up the Ante For Major Biotechs

24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The May 31 short interest data…

1 2 3 4 5 6 … 21

MannKind : MNKD

All MannKind Articles

Short Sellers Can’t Make Up Their Minds on Major Biotechs

Short Sellers Raise the Stakes in Major Biotechs

Short Sellers Hike Their Bets in Major Biotechs

Short Sellers Back Off Major Biotechs

Major Biotechs Have Short Sellers on the Run

Short Sellers Up the Ante in Major Biotechs

Why MannKind Shares More Than Doubled This Week

Short Sellers Run for Cover From Major Biotechs

Why Have Short Sellers Backed Off Major Biotechs?

Mannkind, Tesaro Can’t Escape Monday’s 52-Week Low Club

Symantec, Tesaro Plunge into Friday’s 52-Week Low Club

Major Biotechs See a Rising Tide of Short Interest

Short Sellers Back Off Major Biotechs

Short Sellers Run for Cover From Major Biotechs

Short Sellers Up the Ante For Major Biotechs

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

NVIDIA’s New Quantum‑AI Models Are Impressive — and the Market Doesn’t Seem Ready to Price the Step‑Change

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple's $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

MannKind : MNKD

All MannKind Articles

Short Sellers Can’t Make Up Their Minds on Major Biotechs

Short Sellers Raise the Stakes in Major Biotechs

Short Sellers Hike Their Bets in Major Biotechs

Short Sellers Back Off Major Biotechs

Major Biotechs Have Short Sellers on the Run

Short Sellers Up the Ante in Major Biotechs

Why MannKind Shares More Than Doubled This Week

Short Sellers Run for Cover From Major Biotechs

Why Have Short Sellers Backed Off Major Biotechs?

Mannkind, Tesaro Can’t Escape Monday’s 52-Week Low Club

Symantec, Tesaro Plunge into Friday’s 52-Week Low Club

Major Biotechs See a Rising Tide of Short Interest

Short Sellers Back Off Major Biotechs

Short Sellers Run for Cover From Major Biotechs

Short Sellers Up the Ante For Major Biotechs

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

NVIDIA’s New Quantum‑AI Models Are Impressive — and the Market Doesn’t Seem Ready to Price the Step‑Change

Featured Reads

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple's $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not